Adicet Bio Inc. (ACET, Financial) experienced a significant stock price drop of 5.43%, trading at $0.965 per share with a volume of 279,487 shares and a turnover rate of 0.34%. The stock's amplitude reached 6.91%. Recent financial reports show zero revenue, a net loss of $30.48 million, and earnings per share at -$0.34. The gross profit stands at -$1.59 million, with a P/E ratio of -0.57. Among eight rating institutions, 75% recommend buying, while 25% suggest holding.
In the biotechnology sector, which fell by 1.15%, companies like Cero Therapeutics and Trevi Therapeutics saw significant gains. Adicet Bio focuses on developing γ δ T cell therapies for cancer, with its lead product ADI-001 targeting CD20 for autoimmune diseases and aggressive B-cell non-Hodgkin lymphoma.
